| Objective To explore the safety and efficacy of vitamin E combined with raloxifene on the treatment of postmenopausal osteoporosis. Methods A total of120 postmenopausal women were randomly divided into the treatment group and the control group. Postmenopausal women in the treatment group received vitamin E combined with raloxifene and those in the control group received raloxifene only. Bone mineral density (BMD), serum bone metabolic index, cytokine level, the incidence of adverse reactions, and the incidence of fracture were measured in the two groups before and after 12 months of the treatment. Results BMD of the lumbar vertebrae (L1-4) and the left femoral neck increased significantly after 12 months of the intervention, while BMD of the treatment group was significantly higher than that of the control group (P<0.05). After 12 months of the intervention, the levels of BGP, ALP, IL-6, TNF-α, IL-10, and TGF-β1 of both groups changed significantly. The levels of BGP, ALP, IL-6, TNF-α, IL-10, and TGF-β1 changed more obviously in the treatment group compared with the control group (P<0.05). The incidence of fracture decreased significantly in the treatment group compared with the control group (P<0.05). The adverse drug reactions were not significantly different between the two groups (P>0.05). Conclusion Vitamin E combined with raloxifene can effectively protect the hip and lumbar vertebra BMD, change the level of bone metabolism and inflammatory factors, reduce the incidence of fracture, and the safety is better. |